Servei d'Oncologia Radioteràpica, Consorci Sanitari de Terrassa, Institut Oncològic del Vallès (CST-HGC-CSPT), Ctra, Torrebonica s/n, 08227 Terrassa-Barcelona, Spain.
BMC Cancer. 2011 Jun 24;11:267. doi: 10.1186/1471-2407-11-267.
Extrahepatic biliary duct cancers (EBDC) are uncommon malignancies characterized by a poor prognosis with high rate of loco-regional recurrence. The purpose of the present study is to assess the feasibility and the potential impact of adjuvant radiotherapy (RT) in a series of patients treated in one institution.
Twenty three patients with non-metastatic bile duct cancer treated surgically with curative intent (4 gallbladder, 7 ampullary and 12 cholangiocarcinoma) received 3D conformal external beam RT to a median total dose of 50.4 Gy. Concurrent chemotherapy based on 5-FU was delivered to 21 patients (91%). Surgical margins were negative in 11 patients (48%), narrow in 2 (9%), and microscopically involved in 8 (35%). Eleven patients (55%) had metastatic nodal involvement. The average follow-up time for all patients was 30 months (ranging from 3-98).
Acute gastrointestinal grade 2 toxicity (RTOG scale) was recorded in 2 patients (9%). Nausea or vomiting grade 1 and 2 was observed in 8 (35%) and 2 patients (9%) respectively. Only one patient developed a major late radiation-induced toxicity. The main pattern of recurrence was both loco-regional and distant (liver, peritoneum and/or lung). No difference was observed in loco-regional control according to the tumor location. The 5-year actuarial loco-regional control rate was 48.3% (67% and 30% for patients operated on with negative and positive/narrow/unknown margins respectively, p=0.04). The 5-year actuarial overall survival was of 35.9% for the entire group (61.4% in case of negative margins and 16.7% in case of positive/narrow/unknown margins, p=0.07).
Postoperative RT with 50-60 Gy is feasible with acceptable acute and late toxicities. The potential benefit observed in our series may support the use of adjuvant RT in patients with locally advanced disease. Prospective randomized trials are warranted to confirm definitively the role of RT in this tumor location.
肝外胆管癌(EBDC)是一种罕见的恶性肿瘤,其预后较差,局部复发率较高。本研究的目的是评估在一个机构治疗的一系列患者中辅助放疗(RT)的可行性和潜在影响。
23 例接受根治性手术治疗的非转移性胆管癌患者(4 例胆囊癌、7 例壶腹癌和 12 例胆管癌)接受了中位总剂量为 50.4Gy 的 3D 适形外照射 RT。21 例患者(91%)接受了基于 5-FU 的同期化疗。11 例患者(48%)的手术切缘阴性,2 例(9%)为窄切缘,8 例(35%)为显微镜下累及。11 例患者(55%)有淋巴结转移。所有患者的平均随访时间为 30 个月(3-98 个月)。
2 例患者(9%)出现急性胃肠道 2 级毒性(RTOG 分级)。8 例(35%)和 2 例(9%)患者出现恶心或呕吐 1 级和 2 级。只有 1 例患者发生严重的迟发性放射性毒性。复发的主要模式是局部和远处(肝、腹膜和/或肺)。根据肿瘤位置,局部区域控制无差异。5 年局部区域无复发生存率为 48.3%(阴性切缘患者为 67%,阳性/窄/未知切缘患者为 30%,p=0.04)。全组 5 年总生存率为 35.9%(阴性切缘患者为 61.4%,阳性/窄/未知切缘患者为 16.7%,p=0.07)。
50-60Gy 的术后 RT 是可行的,急性和迟发性毒性可接受。我们的研究结果观察到的潜在益处可能支持在局部进展性疾病患者中使用辅助 RT。需要前瞻性随机试验来明确 RT 在该肿瘤部位的作用。